Clear Filters
11 results
  • A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery. - NCT05296681

    PRIMARY ENDPOINT: Dose Intensity of Irinotecan administered (mg/m2/week) SECONDARY ENDPOINTS: 1. Reduction in % Patients Needing Dose Modification for Diarrhea 2. Toxicity Grade of diarrhea 3. Response Rate 4. Time to Progression-free survival EXPLORATORY ENDPOINTS: 1. 16S rRNA gene sequencing to reveal changes of the gut microbiota including institution of foundation guilds and restoration of healthy microbiome 2. Short chain fatty acids analysis (promotion of acetic and butyric acid production) 3. Markers for gut inflammation such as fecal lipocalin 2 4. Gut barrier function test to see if the restoration of healthier gut microbiota would improve gut barrier function.

    View All Details

    • Protocol Number:
      072201

    • Principal Investigator:
      Howard Hochster

    • Phase:
      Phase II

    • Scope:
      Local

    • Applicable Disease Sites:
      Colon

    • Therapies Involved:
      Chemotherapy (NOS) Chemotherapy multiple agents systemic

    • Drugs Involved:
      IRINOTECAN NBT-NM108

    Read Inclusion & Exclusion Criteria

    Inclusion Criteria

    • Biopsy proven and metastatic colon cancer
    • Candidate for Second-line or later line therapy with irinotecan-based chemotherapy regimen with starting dose of irinotecan at 180 mg/m2 q2w.Participants who have had prior irinotecan will be eligible if they are off irinotecanfor at least three months and stools have returned to baseline consistency.
    • Performance Status (PS) 0-1
    • Lab values as acceptable for trials: Absolute Neutrophil Count( ANC) >1500/uL; Creatinine < 1.5 x Upper Limit of Normal (ULN); Transaminases < 5x ULN; Bilirubin < 1.5 x ULN; Albumin > 3.0 g/dL
    • No known UGTA1A* genotype

    Exclusion Criteria

    • Grade two diarrhea or greater (4-6 movements per day over baseline)
    • Inability to take oral supplements
    • Current antibiotic therapy
    • Baseline grade 3-4 diarrhea Participants with grade two diarrhea should undergo stool evaluation with stool test for bacteria (Salmonella, Shigella, Campylobacter, Yersinia Mycobacterium), bacterial toxin (Clostridium difficile), ova and parasites (Giardia, Entamoeba, Isospora, Cyclospora, Cryptosporidium, Microsporidium), or viruses (Cytomegalovirus), associated with an ongoing active infection and diarrhea. They will be eligible if this evaluation shows no infection.
    • History of the following infections and/or disease which could lead to diarrhea:
    • History of prior positive gastrointestinal biopsy, gastrointestinal culture, or stool test for bacteria (Salmonella, Shigella, Campylobacter, Yersinia, Mycobacterium), bacterial toxin (Clostridium difficile), ova and parasites (Giardia, Entamoeba, Isospora, Cyclospora, Cryptosporidium, Microsporidium), or viruses (Cytomegalovirus), associated with an ongoing active infection and diarrhea unless fully treated with at least three months normal stool.
    • History of ulcerative colitis, Crohn's disease, celiac sprue (gluten-enteropathy), chronic pancreatitis, malabsorption, or any other gastrointestinal disease associated with diarrhea.

    Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site www.clinicaltrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

    For further information about clinical trials, please contact us at 732-235-7356 or 844-CANCERNJ.

    • Cooperman Barnabas Medical Center
    • Monmouth Medical Center
    • Monmouth Medical Center Southern Campus
    • Community Medical Center
    • Newark Beth Israel Medical Center
    • Jersey City Medical Center
    • RWJ University Hospital Hamilton
    • Robert Wood Johnson University Hospital
    • RWJ University Hospital Somerset
    • Rutgers Cancer Institute
    • Trinitas Regional Medical Center – Williamson Street Campus
  • A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer. - NCT06662786

    Primary: To compare PFS Secondary: - To further assess additional measures of clinical benefit - To assess safety - To assess disease symptoms, treatment tolerability, and HRQoL

    View All Details

    • Protocol Number:
      072405

    • Principal Investigator:
      Patrick Boland

    • Phase:
      Phase III

    • Scope:
      National

    • Applicable Disease Sites:
      Colon

    • Therapies Involved:
      Chemotherapy multiple agents systemic

    • Drugs Involved:
      Amivantamab mFOLFOX6

    Read Inclusion & Exclusion Criteria

    Inclusion Criteria:

    • Have histologically or cytologically confirmed adenocarcinoma of the left-sided colorectal cancer. Participants must have unresectable or metastatic disease
    • Be diagnosed to have Kirsten rat sarcoma viral oncogene (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type (WT) tumor as determined by local testing
    • Must agree to the submission of fresh tumor tissue
    • Have measurable disease according to RECIST v1.1
    • Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 or 1

    Exclusion Criteria:

    • Has medical history of (noninfectious) interstitial lung disease (ILD) /pneumonitis/pulmonary fibrosis or has current ILD/pneumonitis/pulmonary fibrosis, or where suspected ILD/pneumonitis/pulmonary fibrosis cannot be ruled out by imaging at screening
    • Has known allergies, hypersensitivity, or intolerance to excipients of any of the following: (a) amivantamab or cetuximab, (b) any component of mFOLFOX6 and, (c) any component of FOLFIRI
    • Has a prior or concurrent second malignancy other than the disease under study or one whose natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
    • Participant with known mismatch repair deficiency (dMMR)/ high microsatellite instability (MSI-H) status and human epidermal growth factor receptor 2 (HER2)-positive/amplified tumor
    • Has prior exposure to any agents that target epidermal growth factor receptor (EGFR) or mesenchymal epithelial transition (MET)

    Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site www.clinicaltrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

    For further information about clinical trials, please contact us at 732-235-7356 or 844-CANCERNJ.

    • Cooperman Barnabas Medical Center
    • Monmouth Medical Center
    • Newark Beth Israel Medical Center
    • RWJ University Hospital Somerset
  • Choices About Genetic Testing And Learning Your Risk with Smart Technology (CATALYST). - NCT06184867

    The study's objectives are to: 1) finalize the development and optimize usability of the CATALYST digital intervention (i.e., RA also known as relational assistant (RA)); 2) evaluate the feasibility and acceptability of a streamlined cancer genomic care delivery in cancer survivors. Participants will be randomized to one of two study arms which are the RA intervention vs. enhanced usual care (EUC); and 3) Conduct a process evaluation to measure barriers/facilitators to GC, GT and use of the CATALYST intervention and engagement with the RA.

    View All Details

    • Protocol Number:
      132307

    • Principal Investigator:
      Anita Y Kinney

    • Phase:
      N/A

    • Scope:
      Local

    • Applicable Disease Sites:
      Breast, Colon, Other Female Genital, Ovary, Pancreas, Prostate

    Read Inclusion & Exclusion Criteria

    Inclusion Criteria:

      User/Usability Testing 1. Age 18 or older 2. Diagnosed with ovarian, fallopian tube, peritoneal, breast, pancreatic, colorectal, endometrial or prostate cancer 3. Speak/read and understand English 4. Capable of providing informed consent 5. Have Internet access (via smartphone, tablet, or computer)Randomized Feasibility Trial 1. Age 18 or older 2. Diagnosed with ovarian, fallopian tube, peritoneal, breast, pancreatic, colorectal, endometrial or prostate cancer 3. Meet National Comprehensive Cancer Network (NCCN) criteria for germline GT 4. Speak/read and understand English 5. Capable of providing informed consent 6. Have Internet access (via smartphone, tablet or computer)

    Exclusion Criteria:

      Participants will be 18 years of age or older because germline genetic testing isgenerally not recommended in children when the test results would not impact clinicalmanagement. Participants from the user and usability testing phases are not eligible forthe feasibility trial. Feasibility trial participants cannot have previously undergonegermline GT for hereditary cancer risk.

    Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site www.clinicaltrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

    For further information about clinical trials, please contact us at 732-235-7356 or 844-CANCERNJ.

    • Rutgers Cancer Institute
  • Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease. - NCT05174169

    Primary Objective ctDNA-ve Cohort (Arms 1 + 2): Phase II: To compare time to ctDNA (+ve) status in ctDNA (-ve) cohort following resection of stage III colon cancer treated with immediate vs delayed (based on serial ctDNA surveillance) chemotherapy. Time to positive event is defined as time from randomization to the first ctDNA positive result for the immediate arm (Arm 1) and to the 2nd ctDNA positive result for the delayed arm (Arm 2) to allow for the potential effect of delayed adjuvant chemotherapy. Patients recurred without a positive ctDNA result will be considered to have ctDNA positive status at the time of recurrence for both study arms. Phase III: To compare time to DFS event (recurrence, second primary colorectal cancer or death) in ctDNA (-ve) cohort following resection of stage III colon cancer treated with immediate vs delayed (based on serial ctDNA surveillance) chemotherapy. ctDNA+ve Cohort (Arms 3 + 4): Phase II and III: To compare time to DFS event (recurrence, second primary colorectal cancer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (or capecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months. Secondary Objectives - To describe the prevalence of detectable ctDNA in patients with stage III colon cancer following surgical resection. The finding will be reported together with the main results of the Phase II portion of the trial. - To estimate time-to-event outcomes (overall survival and time to recurrence) by ctDNA marker status and treatment. - To assess the compliance of adjuvant chemotherapy.

    View All Details

    • Protocol Number:
      072207

    • Principal Investigator:
      Howard Hochster

    • Phase:
      Phase II/III

    • Scope:
      National

    • Applicable Disease Sites:
      Colon

    • Therapies Involved:
      Chemotherapy (NOS) Chemotherapy multiple agents systemic Radiotherapy

    • Drugs Involved:
      CAPOX mFOLFIRINOX mFOLFOX6

    Read Inclusion & Exclusion Criteria

    Inclusion Criteria:

      The patient must have an ECOG performance status of 0 or 1.Patients must have histologically/pathologically confirmed Stage IIB, IIC, or Stage IIIcolon adenocarcinoma with R0 resection according to AJCC 8th edition criteria.No radiographic evidence of overt metastatic disease within 45 days prior to Step 1/Studyentry (CT with IV contrast or MRI imaging is acceptable and must include chest, abdomen,and pelvis).The distal extent of the tumor must be greater than or equal to 12 cm from the anal vergeon colonoscopy or above the peritoneal reflection as documented during surgery or onpathology specimen (i.e., excluding rectal adenocarcinomas warranting treatment withchemoradiation).The patient must have had an en bloc complete gross resection of tumor (curativeresection). Patients who have had a two-stage surgical procedure, to first provide adecompressive colostomy and then in a later procedure to have the definitive surgicalresection, are eligible.The resected tumor specimen and a blood specimen from patients with Stage IIB, IIC, orStage III colon cancer must have central testing for ctDNA using the Signatera™ assay byNatera (after Step 1/Study entry and before Step2/Randomization). Patient must havesufficient tissue to meet protocol requirements. This blood specimen for the Signateraassay must be collected after surgery (and recommended at least 14 days post surgery).Tumor must be documented as microsatellite stable or have intact mismatch repair proteinsthrough CLIA-approved laboratory testing. Patients whose tumors are MSI-H or dMMR areexcluded.The treating investigator must deem the patient a candidate for all potential agents usedin this trial (5FU, LV, oxaliplatin and irinotecan).The interval between surgery (post-operative Day 7) and Step 1/Study entry must be nomore than 60 days. NOTE: Step 1/Study Entry may occur as early as post operative Day 7,but it cannot occur beyond 60 days from the actual date of the patient's surgery.Availability and provision of adequate surgical tumor tissue for molecular diagnosticsand confirmatory profiling.Adequate hematologic function within 28 days before Step 1/Study entry defined asfollows:
    • Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3;
    • Participants with benign ethnic neutropenia (BEN): ANC less than 1300 mm3 are eligible.
    • BEN (also known as constitutional neutropenia) is an inherited cause of mild or moderate neutropenia that is not associated with any increased risk for infections or other clinical manifestations. BEN is referred to as ethnic neutropenia because of its increased prevalence in people of African descent and other specific ethnic groups.
    • Platelet count must be greater than or equal to 100,000/mm3; and
    • Hemoglobin must be greater than or equal to 9 g/dL.Adequate hepatic function within 28 days before Step 1/Study entry defined as follows:
    • total bilirubin must be less than or equal to ULN (upper limit of normal) for the lab and
    • alkaline phosphatase must be less than 2.5 x ULN for the lab; and
    • AST and ALT must be less than 2.5 x ULN for the lab.Adequate renal function within 28 days before Step 1/Study entry defined as serumcreatinine less than or equal to 1.5 x ULN for the lab or measured or calculatedcreatinine clearance greater than or equal to 50 mL/min using the Cockroft-Gault formulafor patients with creatinine levels greater than 1.5 x ULN for the lab.For Women Creatinine Clearance (mL/min) = (140 - age) x weight (kg) x 0.85 72 x serumcreatinine (mg/dL) For Men Creatinine Clearance (mL/min) = (140 - age) x weight (kg) 72 xserum creatinine (mg/dL) NOTE: Adjusted body weight (AdjBW) should be used for patientsthat have BMI greater than or equal to 28 (less than or equal to 30% above IBW).HIV-infected patients on effective anti-retroviral therapy with undetectable viral loadwithin 6 months are eligible for this trial.Pregnancy test (urine or serum according to institutional standard) done within 14 daysbefore Step 1/Study entry must be negative (for women of childbearing potential only).Patients receiving a coumarin-derivative anticoagulant must agree to weekly monitoring ofINR if they are randomized to Arm 1 or Arm 3 and receive capecitabine.Eligibility Criteria for Cohort A Arm-2 patients on Second RandomizationPatient must have developed a ctDNA +ve assay during serial monitoring.Patient's willingness to be re-randomized affirmed.The patient must continue to have an ECOG performance status of 0 or 1.No radiographic evidence of overt metastatic disease.Pregnancy test (urine or serum according to institutional standard) done within 14 daysbefore second randomization must be negative (for women of childbearing potential only).Adequate hematologic function within 28 days before second randomization defined asfollows:
    • Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3;
    • Participants with benign ethnic neutropenia (BEN): ANC less than 1300 mm3 are eligible.
    • BEN (also known as constitutional neutropenia) is an inherited cause of mild or moderate neutropenia that is not associated with any increased risk for infections or other clinical manifestations. BEN is referred to as ethnic neutropenia because of its increased prevalence in people of African descent and other specific ethnic groups.
    • Platelet count must be greater than or equal to 100,000/mm3; and
    • Hemoglobin must be greater than or equal to 9 g/dL.Adequate hepatic function within 28 days before second randomization defined as follows:
    • total bilirubin must be less than or equal to ULN (upper limit of normal) for the lab and
    • alkaline phosphatase must be less than 2.5 x ULN for the lab; and
    • AST and ALT must be less than 2.5 x ULN for the lab.Adequate renal function within 28 days before second randomization defined as serumcreatinine less than or equal to 1.5 x ULN for the lab or measured or calculatedcreatinine clearance greater than or equal to 50 mL/min using the Cockroft-Gault formulafor patients with creatinine levels greater than 1.5 x ULN for the lab.For Women Creatinine Clearance (mL/min) = (140 - age) x weight (kg) x 0.85 72 x serumcreatinine (mg/dL) For Men Creatinine Clearance (mL/min) = (140 - age) x weight (kg) 72 xserum creatinine (mg/dL)

    Exclusion Criteria:

      Colon cancer histology other than adenocarcinoma (i.e., neuroendocrine carcinoma,sarcoma, lymphoma, squamous cell carcinoma, etc.).Pathologic, clinical, or radiologic overt evidence of metastatic disease. This includesisolated, distant, or non-contiguous intra-abdominal metastases, even if resected.Tumor-related bowel perforation.History of prior invasive colon malignancy, regardless of disease-free interval.History of bone marrow or solid organ transplantation (regardless of currentimmunosuppressive therapy needs). Bone grafts, skin grafts, corneal transplants andorgan/tissue donation are not exclusionary.Any prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapyadministered as treatment for colorectal cancer (e.g., primary colon adenocarcinomas forwhich treatment with neoadjuvant chemotherapy and/or radiation is warranted are notpermitted). EXCEPTION: one cycle of chemotherapy (regimen per treating physicians'discretion - 5-FU or capecitabine with or without oxaliplatin) is allowed but notrequired after consent. The optional cycle of chemotherapy should be started greater thanor equal to 4 weeks from surgery and while awaiting Step 2 randomization.Other invasive malignancy within 5 years before Step 1/Study entry. Exceptions arecolonic polyps, non-melanoma skin cancer or any carcinoma-in-situ.Synchronous primary rectal and/ or colon cancers.Patients with known history or current symptoms of cardiac disease, or history oftreatment with cardiotoxic agents, should have a clinical risk assessment of cardiacfunction using the New York Heart Association Functional Classification. To be eligiblefor this trial, patients should be class 2B or better.Sensory or motor neuropathy greater than or equal to grade 2, according to CTCAE v5.0.Blood transfusion within two weeks before collection of blood for central ctDNA testing.Active seizure disorder uncontrolled by medication.Active or chronic infection requiring systemic therapy.Known homozygous DPD (dihydropyrimidine dehydrogenase) deficiency.Patients known to have Gilbert's Syndrome or homozygosity for UGT1A1*28 polymorphism.Pregnancy or lactation at the time of Step 1/Study entry.Co-morbid illnesses or other concurrent disease that would make the patient inappropriatefor entry into this study (i.e., unable to tolerate 6 months of combination chemotherapyor interfere significantly with the proper assessment of safety and toxicity of theprescribed regimens or prevent required follow-up).Ineligibility Criteria for Cohort A Arm-2 patients on Second RandomizationPregnancy or lactation at the time of randomization.No longer a candidate for systemic chemotherapy (FOLFOX, CAPOX, and mFOLFIRINOX) in theopinion of the treating investigator.

    Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site www.clinicaltrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

    For further information about clinical trials, please contact us at 732-235-7356 or 844-CANCERNJ.

    • Cooperman Barnabas Medical Center
    • Monmouth Medical Center
    • Monmouth Medical Center Southern Campus
    • Community Medical Center
    • Newark Beth Israel Medical Center
    • Jersey City Medical Center
    • RWJ University Hospital Hamilton
    • RWJ University Hospital Somerset
    • Rutgers Cancer Institute
    • Trinitas Regional Medical Center – Williamson Street Campus
  • Optimizing Colorectal Cancer Screening Among Patients with Diabetes in Safety-Net Primary Care Settings: Targeting Implementation Approaches. - NCT05785780

    Aim 1: To examine the effects of CRC screening implementation approaches on racial/ethnic disparities among primary care patients with diabetes. Aim 2: Identify multi-level change objectives to implement targeted CRC screening for patients with diabetes in safety-net settings.

    View All Details

    • Protocol Number:
      002056

    • Phase:
      N/A

    • Scope:
      Local

    • Applicable Disease Sites:
      Colon

    Read Inclusion & Exclusion Criteria

    Inclusion Criteria:

    • Diagnosis of diabetes mellitus;
    • Participants not up-to-date with CRC screening based on electronic health record (e.g. FOBT/FIT in last year; flexible sigmoidoscopy within four years; or colonoscopy within nine years);
    • Age-eligible for CRC screening (50-74 years of age);
    • Participants in process of undergoing screening are eligible for participation if they have a FIT/FOBT incomplete test ordered for more than six months or a sigmoidoscopy or colonoscopy referral not completed for greater than one year.

    Exclusion Criteria:

      • Medical conditions not concordant with standard CRC screening intervals (e.g. prior CRCdiagnosis, inflammatory bowel disease, renal failure, etc.).

    Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site www.clinicaltrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

    For further information about clinical trials, please contact us at 732-235-7356 or 844-CANCERNJ.

  • Personalized Oncology Promoting Equity for Black Lives (PROPEL). - NCT06073626

    The specific aims of this study are: 1) Test the efficacy of a culturally tailored and interactive electronic relational agent (RA) intervention vs. enhanced usual care (EUC) consisting of clinical letter and genetic recommendation on engagement in genetic education and genetic testing uptake; 2) Evaluate the impact of the RA vs. EUC on informed decision-making and psychosocial outcomes; and 3) Explore potential mechanisms by assessing mediators and moderations of efficacy.

    View All Details

    • Protocol Number:
      132309

    • Principal Investigator:
      Anita Y Kinney

    • Phase:
      N/A

    • Scope:
      National

    • Applicable Disease Sites:
      Breast, Colon, Corpus Uteri, Ovary, Pancreas, Prostate

    Read Inclusion & Exclusion Criteria

    Inclusion Criteria:

    • 18-80 years of age
    • Identify as Black or African American
    • At least 6-months post diagnosis with any of the following cancers: breast, ovarian, uterine, prostate, colorectal, pancreatic
    • Have received treatment or follow-up oncology care at one of the participating sites in the prior two years.
    • Meet National Comprehensive Cancer Network criteria for germline GT
    • Able to read and speak in English.

    Exclusion Criteria:

    • Do not speak English
    • Unable to access the Internet
    • Have previously undergone germline genetic testing for hereditary cancer risk
    • Are unable to provide informed consent

    Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site www.clinicaltrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

    For further information about clinical trials, please contact us at 732-235-7356 or 844-CANCERNJ.

    • Cooperman Barnabas Medical Center
    • Monmouth Medical Center
    • Monmouth Medical Center Southern Campus
    • Clara Maass Medical Center
    • Community Medical Center
    • Newark Beth Israel Medical Center
    • Jersey City Medical Center
    • RWJ University Hospital Hamilton
    • Robert Wood Johnson University Hospital
    • RWJ University Hospital Somerset
    • Rutgers Cancer Institute
    • Trinitas Regional Medical Center – Williamson Street Campus
  • Practices, knowledge and beliefs of colorectal cancer patients and their providers prescription practices regarding anemia and oral iron supplementation

    1) To assess the prevalence, types and dosage of oral iron supplements which oncology providers prescribe to CRC patients by reviewing CRC patients' electronic health records. 2) To determine the percentage of CRC patients diagnosed with IDA who follow through with their prescribed oral iron treatment, the amount and types of oral iron supplements which they take, factors associated with the use of oral iron supplements and their knowledge on using oral iron supplements using a patient self-report online survey. 3) To elicit the modal salient beliefs of CRC survivors underlying informed decision-making regarding oral iron supplementation via focused face-to-face interviews.

    View All Details

    • Protocol Number:
      132003

    • Principal Investigator:
      Carolyn J Heckman

    • Phase:
      N/A

    • Scope:
      Local

    • Applicable Disease Sites:
      Colon, Rectum

    • Rutgers Cancer Institute
  • Preoperative Plasma ctDNA Detection in Early Stage Cancer: A Proof-of-Concept Evaluation

    The primary objective of this study is to evaluate the feasibility of using a novel, highly specific and sensitive SuperSelective PCR approach to detect specific oncogenic mutations in the plasma of patients with resectable, early-stage lung and colon cancers, which will be achieved by correlating those results with disease site, histology, pathological stage, tumor variant allele frequency, and volume. Secondarily, we will assess the effectiveness of this approach in detecting residual disease (correlated with 2-year disease-free survival and overall survival outcomes) when applied at 6-month intervals over a total of 2 years on the study. Lastly, we will explore the sensitivity of SuperSelective PCR in detecting ctDNA of cancer patients (regardless of tumor type) with known tumor alterations that were not previously detected using commercially available, CLIA-certified ctDNA analyses.

    View All Details

    • Protocol Number:
      032308

    • Principal Investigator:
      Missak Haigentz

    • Phase:
      N/A

    • Scope:
      Local

    • Applicable Disease Sites:
      Colon, Lung

    • Rutgers Cancer Institute
  • ScreenNJ Resource and Evaluation Unit

    1. Identify evidence-based strategies and lessons learned from previous CRC and lung cancer screening studies, particularly among underserved and vulnerable populations 2. Develop an interactive web-based platform for shared learning and collaboration among the ScreenNJ programs 3. Compare Reach, Effectiveness, and Adoption of the ScreenNJ colorectal and lung cancer screening programs 4. Identify facilitators and barriers to Implementation and potential Maintenance of the ScreenNJ colorectal and lung cancer screening programs

    View All Details

    • Protocol Number:
      131820

    • Phase:
      N/A

    • Scope:
      Local

    • Applicable Disease Sites:
      Colon, Lung

  • Sequential Combined TAS-102 and Oxaliplatin Alternating with TAS-102 and Irinotecan (Sequential TASOXIRI) with Bevacizumab for Late-Line Metastatic Colorectal Cancer. - NCT05806931

    The purpose of this study is to evaluate the disease control rate and time to progression of then sequential combination of oxaliplatin with an alternative anti-metabolite TAS-102 (TAS-OX) as well as irinotecan in combination with TAS-102 (TAS-IRI) + Bevacizumab in late-line metastatic colorectal cancer (mCRC).

    View All Details

    • Protocol Number:
      072303

    • Principal Investigator:
      Howard Hochster

    • Phase:
      Phase II

    • Scope:
      Local

    • Applicable Disease Sites:
      Colon

    • Therapies Involved:
      Chemotherapy multiple agents systemic

    • Drugs Involved:
      BEVACIZUMAB TAS-OX

    Read Inclusion & Exclusion Criteria

    Inclusion Criteria:

    • Histologically confirmed stage IV colon cancer (AJCC 7th edition) that has progressed after standard therapy that included 5-FU, irinotecan, oxaliplatin and appropriate antibody therapy. Antibody therapy with bevacizumab and an anti-EGFR antibody, if RAS wild type, should have been given unless medical reasons have precluded their use. Participants who could not tolerate standard agents because of unacceptable, but reversible toxicity necessitating their discontinuation will be allowed to participate.
    • Participants who had received adjuvant chemotherapy and had recurrence during or within six months of completion of the adjuvant chemotherapy will be allowed to count the adjuvant therapy as one chemotherapy regimen for advanced disease.
    • Progression of disease must be documented on the most recent scan.
    • Presence of measurable disease
    • RAS mutation and MMR status must be determined (or tissue availability for testing if not already determined).
    • Age 18 years or older.
    • ECOG performance status 0-1.
    • Life expectancy of at least three months.
    • Participants with adequate organ function: 1. Absolute neutrophil count (ANC) > 1.5 x 109/L 2. Hemoglobin > 9 g/dL 3. Platelets (PLT) > 70 x 109/L 4. AST/ALT < 5 x ULN 5. Albumin within normal limits for institution
    • Women who are nursing and discontinue nursing prior to enrollment in the program.
    • Ability to take oral medication (i.e., no feeding tube).
    • Participant able and willing to comply with study procedures as per protocol.
    • Participant able to understand and willing to sign and date the written voluntary informed consent form (ICF) at screening visit prior to any protocol-specific procedures.

    Exclusion Criteria:

    • Participants who have previously received TAS-102.
    • Grade 3 or higher peripheral neuropathy (functional impairment).
    • Inability to tolerate irinotecan previously (due to uncontrolled diarrhea)
    • There are no specific exclusions for bevacizumab. Bevacizumab should be given unless there are specific contraindications per the treating investigator, which should be stated. If UPC is >1.0 (as above) hold bevacizumab until proteinuria resolves and then start bevacizumab.
    • Symptomatic CNS metastases requiring treatment.
    • Other active malignancy within the last three years (except for non-melanoma skin cancer or a non-invasive/in situ cancer).
    • Pregnancy or breast feeding.
    • Current therapy with other investigational agents.
    • Active infection with body temperature > 38°C due to infection.
    • Major surgery within prior four weeks (the surgical incision should be fully healed prior to drug administration).
    • Any anticancer therapy within prior two weeks of first dose of study drug.
    • History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102.
    • Current therapy with other investigational agents or participation in another clinical study or any investigational agent received within prior four weeks.
    • Grade 3 or higher hypersensitivity reaction to oxaliplatin or irinotecan, or grade 1-2 hypersensitivity reaction to oxaliplatin not controlled with pre-medication.
    • Has unresolved toxicity of greater than or equal to Common Terminology Criteria for Adverse (CTCAE) Grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation, and platinum-induced neurotoxicity).

    Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site www.clinicaltrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

    For further information about clinical trials, please contact us at 732-235-7356 or 844-CANCERNJ.

    • Cooperman Barnabas Medical Center
    • Monmouth Medical Center
    • Monmouth Medical Center Southern Campus
    • Community Medical Center
    • Newark Beth Israel Medical Center
    • Jersey City Medical Center
    • Robert Wood Johnson University Hospital
    • RWJ University Hospital Somerset
    • Rutgers Cancer Institute
    • Trinitas Regional Medical Center – Williamson Street Campus
  • Video Education with Result Dependent dIsclosure (VERDI) - NCT05225428

    The overall study objective is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers. This developmental work is imperative as the VERDI models utilized at DFCI in research studies #18-411 (ProActive), #17-409 (ProGen), #19-068 (OPT-IN), and #19-652 (GeneBOPP) have been overwhelmingly used in DFCI patients of Caucasian ancestry. While DFCI participants have responded well, in an effort improve the generalizability of VERDI and expand it to a diverse patient population, qualitative feedback is being sought explicitly from patients who self-identify as Black and Latinx patients. A brief qualitative assessment among a small, cohort of English and Spanish speaking Black and Latinx participants will first be conducted to identify refinements to video education (VE) that may increase the utility of the VERDI model for patients in these traditionally underserved populations. Participants in the qualitative assessment study will receive VE exclusively for pretest education, followed by a short interview with research staff regarding their experiences with the VE model. The qualitative assessment study will precede a large-scale randomized controlled trial of VERDI vs standard genetic counseling (SGC), as informed by the results of the developmental study. We hypothesize that the data yielded from the completion of the study objectives will assist in further refining the VERDI model and its use in clinical practices for the purpose of increasing genetic testing uptake and improving patient outcomes in minority populations that have been underrepresented in similar research to date.

    View All Details

    • Protocol Number:
      042207

    • Principal Investigator:
      Deborah L Toppmeyer

    • Phase:
      N/A

    • Scope:
      National

    • Applicable Disease Sites:
      Breast, Colon, Kidney, Melanoma, Skin, Ovary, Pancreas, Prostate, Soft Tissue

    Read Inclusion & Exclusion Criteria

    Inclusion Criteria:

    • Age ≥ 18 years
    • Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma
    • Ability to understand spoken or written English or Spanish in a healthcare context
    • Ability to understand and the willingness to sign a written informed consent document
    • Black or Latinx (qualitative assessment study only)

    Exclusion Criteria:

    • Prior cancer genetic testing
    • Prior germline genetic testing
    • Active hematologic malignancy (e.g. chronic lymphocytic leukemia)
    • Currently pregnant
    • Currently incarcerated

    Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site www.clinicaltrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

    For further information about clinical trials, please contact us at 732-235-7356 or 844-CANCERNJ.

    • Rutgers Cancer Institute